18F-Fluorodeoxyglucose–Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis

Arthritis and Rheumatology

Volumn 70, Issue 3, 2018, Pages 439-449

  Grayson, Peter C ^a   Alehashemi, Sara ^a   Bagheri, Armin A ^a   Civelek, Ali Cahid ^b   Cupps, Thomas R ^c   Kaplan, Mariana J ^a   Malayeri, Ashkan A ^b   Merkel, Peter A ^d   Novakovich, Elaine ^a   Bluemke, David A ^b   Ahlman, Mark A ^b  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; PREDNISONE;

ADULT; AGED; AORTIC ARCH SYNDROME; ARTICLE; BODY MASS; CHILD; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; GIANT CELL ARTERITIS; HUMAN; LARGE VESSEL VASCULITIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; SENSITIVITY AND SPECIFICITY; VASCULITIS; ARTERY; CLINICAL TRIAL; DIAGNOSTIC IMAGING; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADULT; AGED; ARTERIES; BIOMARKERS; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; GIANT CELL ARTERITIS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TAKAYASU ARTERITIS;

EID: 85041590355     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40379     Document Type: Article

References (40)

1. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006;354:496–507.
2. Rosenbaum D, Millon A, Fayad ZA. Molecular imaging in atherosclerosis: FDG PET. Curr Atheroscler Rep 2012;14:429–37.
3. Yamashita H, Kubota K, Mimori A. Clinical value of whole-body PET/CT in patients with active rheumatic diseases. Arthritis Res Ther 2014;16:423.
4. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1–11.
5. Direskeneli H, Aydin SZ, Kermani TA, Matteson EL, Boers M, Herlyn K, et al. Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol 2011;38:1471–9.
6. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med 1994;120:919–29.
7. Maleszewski JJ, Younge BR, Fritzlen JT, Hunder GG, Goronzy JJ, Warrington KJ, et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod Pathol 2017;30:788–96.
8. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318–23.
9. Danve A, O'Dell J. The role of 18F fluorodeoxyglucose positron emission tomography scanning in the diagnosis and management of systemic vasculitis. Int J Rheum Dis 2015;18:714–24.
10. Besson FL, de Boysson H, Parienti JJ, Bouvard G, Bienvenu B, Agostini D. Towards an optimal semiquantitative approach in giant cell arteritis: an F-FDG PET/CT case-control study. Eur J Nucl Med Mol Imaging 2014;41:155–66.
11. Papathanasiou ND, Du Y, Menezes LJ, Almuhaideb A, Shastry M, Beynon H, et al. 18F-fludeoxyglucose PET/CT in the evaluation of large-vessel vasculitis: diagnostic performance and correlation with clinical and laboratory parameters. Br J Radiol 2012;85:e188–94.
12. Walter MA, Melzer RA, Schindler C, Muller-Brand J, Tyndall A, Nitzsche EU. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005;32:674–81.
13. Henes JC, Muller M, Krieger J, Balletshofer B, Pfannenberg AC, Kanz L, et al. [18F] FDG-PET/CT as a new and sensitive imaging method for the diagnosis of large vessel vasculitis. Clin Exp Rheumatol 2008;26 Suppl 49:S47–52.
14. Lehmann P, Buchtala S, Achajew N, Haerle P, Ehrenstein B, Lighvani H, et al. 18F-FDG PET as a diagnostic procedure in large vessel vasculitis: a controlled, blinded re-examination of routine PET scans. Clin Rheumatol 2011;30:37–42.
15. Prieto-Gonzalez S, Depetris M, Garcia-Martinez A, Espigol-Frigole G, Tavera-Bahillo I, Corbera-Bellata M, et al. Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study. Ann Rheum Dis 2014;73:1388–92.
16. Hautzel H, Sander O, Heinzel A, Schneider M, Muller HW. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio. J Nucl Med 2008;49:1107–13.
17. Fuchs M, Briel M, Daikeler T, Walker UA, Rasch H, Berg S, et al. The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging 2012;39:344–53.
18. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990;33:1129–34.
19. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122–8.
20. Grayson PC, Maksimowicz-McKinnon K, Clark TM, Tomasson G, Cuthbertson D, Carette S, et al. Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Ann Rheum Dis 2012;71:1329–34.
21. Sandfort V, Lai S, Ahlman MA, Mallek M, Liu S, Sibley CT, et al. Obesity is associated with progression of atherosclerosis during statin treatment. J Am Heart Assoc 2016;5:e003621.
22. Meller J, Strutz F, Siefker U, Scheel A, Sahlmann CO, Lehmann K, et al. Early diagnosis and follow-up of aortitis with [F]FDG PET and MRI. Eur J Nucl Med Mol Imaging 2003;30:730–6.
23. Newman KA, Ahlman MA, Hughes M, Malayeri AA, Pratt D, Grayson PC. Diagnosis of giant cell arteritis in an asymptomatic patient. Arthritis Rheumatol 2016;68:1135.
24. Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages: implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol 2011;58:603–14.
25. Hyafil F, Cornily JC, Rudd JH, Machac J, Feldman LJ, Fayad ZA. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology. J Nucl Med 2009;50:959–65.
26. Ostberg G. Morphological changes in the large arteries in polymyalgia arteritica. Acta Med Scand Suppl 1972;533:135–59.
27. Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012;64:1720–9.
28. Lee YH, Choi SJ, Ji JD, Song GG. Diagnostic accuracy of 18F-FDG PET or PET/CT for large vessel vasculitis: a meta-analysis. Z Rheumatol 2016;75:924–31.
29. Bucerius J, Hyafil F, Verberne HJ, Slart RH, Lindner O, Sciagra R, et al. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. Eur J Nucl Med Mol Imaging 2016;43:780–92.
30. Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006;55:131–7.
31. Kobayashi Y, Ishii K, Oda K, Nariai T, Tanaka Y, Ishiwata K, et al. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. J Nucl Med 2005;46:917–22.
32. Webb M, Chambers A, Al-Nahhas A, Mason JC, Maudlin L, Rahman L, et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging 2004;31:627–34.
33. Lee SG, Ryu JS, Kim HO, Oh JS, Kim YG, Lee CK, et al. Evaluation of disease activity using F-18 FDG PET-CT in patients with Takayasu arteritis. Clin Nucl Med 2009;34:749–52.
34. Arnaud L, Haroche J, Malek Z, Archambaud F, Gambotti L, Grimon G, et al. Is 18F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum 2009;60:1193–200.
35. Lee KH, Cho A, Choi YJ, Lee SW, Ha YJ, Jung SJ, et al. The role of 18F-fluorodeoxyglucose–positron emission tomography in the assessment of disease activity in patients with Takayasu arteritis. Arthritis Rheum 2012;64:866–75.
36. Tezuka D, Haraguchi G, Ishihara T, Ohigashi H, Inagaki H, Suzuki J, et al. Role of FDG PET-CT in Takayasu arteritis: sensitive detection of recurrences. JACC Cardiovasc Imaging 2012;5:422–9.
37. Karapolat I, Kalfa M, Keser G, Yalcin M, Inal V, Kumanlioglu K, et al. Comparison of F18-FDG PET/CT findings with current clinical disease status in patients with Takayasu's arteritis. Clin Exp Rheumatol 2013;31 Suppl 75:S15–21.
38. Soussan M, Nicolas P, Schramm C, Katsahian S, Pop G, Fain O, et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine (Baltimore) 2015;94:e622.
39. Sheikine Y, Akram K. FDG-PET imaging of atherosclerosis: do we know what we see? Atherosclerosis 2010;211:371–80.
40. Dellavedova L, Carletto M, Faggioli P, Sciascera A, del Sole A, Mazzone A, et al. The prognostic value of baseline F-FDG PET/CT in steroid-naive large-vessel vasculitis: introduction of volume-based parameters. Eur J Nucl Med Mol Imaging 2016;43:340–8.